Conditions: Sickle Cell Anemia
Keywords: Sickle Cell Disease Sickle Cell Anemia Adult
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 62
Healthy volunteers: no

Brief summary:
The purpose of this trial is to assess the safety of Prasugrel in adult patients with sickle cell disease (SCD) by monitoring the rate and severity of hemorrhagic events requiring medical intervention compared to placebo for 30 days.

Detailed description:

Arms:
arm 1: Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel. arm 2: None arm 3: None

Interventions: intervention 1: Prasugrel intervention 2: Placebo
Intervention descriptions: intervention 1: Administered orally, once daily for 30 days. intervention 2: Administered orally, once daily for 30 days.

Protocol document: